Want to join the conversation?
$BIIB expects its full year 2016 revenue to be approx. $11.1Bil to $11.3Bil, which is higher than the 2015 revenue of $10.8Bil. GAAP diluted EPS is expected to be between $16.85 and $17.15. CEO George Scangos said that the company is excited about the potential new launches of BENEPALI, ZINBRYTATM, and an infliximab biosimilar in 2016.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.